RxDoctor Payments DataLook up a doctor →

James Lee, MD

Ophthalmology · Colorado Springs, CONPI 1396772372

Payments from drug & device makers

$451,309in general payments, 2019–2025

Across 443 payments — averaging $1018.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$299K
  • AbbVie$147K
  • Alcon$4K
  • Novartis$381
  • Rxsight Inc$358
  • Johnson & Johnson Surgical Vision, Inc.$212
  • plus $834 from 20 others

What the payments were for

  • Consulting fees$9,25634%
  • Speaking & faculty fees$1,3005%
  • Food & beverage$8,86833%
  • Education$280%
  • Gifts$720%
  • Other$7,47528%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$451,309 in reported general payments places this provider in the 95th percentile of 262 ophthalmology providers in Colorado.

See all ophthalmology providers in Colorado

Medicare billing

Part B allowed, 2024
$466,634
Medicare patients
1,016
Services billed
4,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine42$52,026
XiidraLifitegrast29$33,218
LumiganBimatoprost64$30,866
Prednisolone Acetate470$23,380
CombiganBrimonidine Tartrate/Timolol30$11,406
CequaCyclosporine13$8,659
Ketorolac Tromethamine389$8,450
MoxifloxacinMoxifloxacin Hcl354$8,434
Cyclosporine14$6,812
Latanoprost524$6,074
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol40$6,048
SimbrinzaBrinzolamide/Brimonidine Tart25$4,996
Travoprost19$3,827
Gatifloxacin72$3,160
TobradexTobramycin/Dexamethasone11$2,906

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$146,798$94,298136 claims
Bausch & Lomb Americas Inc.Xiidra$23$33,21829 claims
Sun Pharmaceutical Industries Inc.Cequa$41$8,65913 claims
AlconSimbrinza$3,598$4,99625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 262 ophthalmology providers in Colorado.

Other ophthalmology in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →